Dr. Reddy’s Laboratories – pharmaceutical daily

April 2, 2019 Off

Promius Pharma, LLC. (a Wholly Owned Subsidiary of Dr. Reddy’s Laboratories Ltd.) Announces the Sale and Assignment of the US Rights for Its Marketed Dermatology Brands to Encore Dermatology

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…

November 21, 2018 Off

Indivior trusts its portfolio, aware of challenges for Suboxone

By Dino Mustafić

Indivior PLC said Wednesday said in a statement it is dissapointed by the US District Court for the District of…

November 26, 2015 Off

FDA may withhold approval of Dr. Reddy’s new applications or supplements listing

By Dino Mustafić

The FDA said that, until Dr. Reddy’s complete all corrections and FDA confirms its compliance with CGMP, it may withhold approval of any new applications or supplements listing Dr. Reddy as a drug product or API manufacturer.